[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasolabial-folds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasolabial-folds":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100658846","a-study-to-confirm-safety-and-effectiveness-of-radiesse-injectable-implant-for-the-correction-of-moderate-to-severe-nasolabial-folds-100658846",false,"NCT07856797","A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds","A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds","Radiesse China","Inclusion Criteria:\n\n* WSRS score of 3 (moderate) or 4 (severe) in both right and left NLFs, as determined live by the treating investigator. The WSRS score for the right and the left NLF does not have to be equal.\n* Willing to abstain from other aesthetic treatments in the NLF area during study participation.\n\nExclusion Criteria:\n\n* Prior dermal filler or implant material detectable in the NLF area by ultrasound.\n* Active infection or acute inflammation at treatment sites.\n* Hyaluronic Acid or collagen filler treatment in NLFs within 12 months.\n* CaHA or Poly L-Lactic Acid filler treatment in NLFs within 24 months.\n* Recent facial dermal therapies in the midface region within the past 6 months.\n* Prior facial surgery or implants that could interfere with assessments.","ALL","18 Years",{"count":20,"type":21},163,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.",[27],"Nasolabial Folds","NOT_YET_RECRUITING","2026-09-29",{"date":31,"type":32},"2026-10-05","ACTUAL",{"date":34,"type":21},"2026-10",{"date":36,"type":21},"2029-02",{"name":38,"class":39},"Merz North America, Inc.","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100658621","dermal-evaluation-of-facetem-s-in-nasolabial-folds-esthetics-improvement-define-study-100658621","NCT07855224","Dermal Evaluation of Facetem™ S in Nasolabial Folds Esthetics Improvement: DEFINE Study","A Multicenter, Prospective, Non-randomized, Uncontrolled, Post-market Clinical Follow-up (PMCF) Study to Evaluate the Performance and Safety of Facetem™ S Dermal Fillers for the Correction of Nasolabial Folds","DEFINE","Inclusion Criteria:\n\n1. Male or female, over the age of 18.\n2. Subjects with moderate-to-severe nasolabial folds (WSRS Grade 3-4) on both sides of the face.\n3. Signed informed consent.\n4. Women of childbearing potential must be using a highly effective method of contraception throughout the study period.\n5. Agrees not to undergo any other facial aesthetic procedure that may interfere with the evaluation of nasolabial folds during study participation.\n6. Is willing and able to attend all scheduled follow-up visits and comply with all study requirements.\n\nExclusion Criteria:\n\n1. Any history of treatment with permanent or non-absorbable facial fillers, including silicone, polymethyl methacrylate (PMMA), polytetrafluoroethylene (PTFE), hydroxyethyl methacrylate (HEMA), dextran-based fillers, or other non-resorbable filler materials. Prior treatment with biostimulatory fillers, including poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), or other polylactic acid-based fillers, within the past 24 months is also exclusionary. The presence of any foreign particulate material at the treatment site, including liquid silicone or residual filler material, is exclusionary.\n2. Prior botulinum toxin treatment in the treatment area within the past 12 months.\n3. Any prior facial surgical procedures, including plastic surgery or thread lift, or the presence of a permanent surgical implant that could interfere with performance assessments.\n4. Prior treatment within the past 12 months with any dermal filler (e.g., hyaluronic acid, CaHA, collagen-based fillers) in the area to be treated.\n5. Prior treatment within the past 6 months with facial dermal therapies, including but not limited to ablative or non-ablative laser therapy, radiofrequency treatment, chemical or mechanical peels, non-invasive skin-tightening procedures, or planned treatments of this nature during the study period.\n6. History of severe allergic reactions, including anaphylaxis, or known hypersensitivity to any components of the study treatment.\n7. Known bleeding disorder or anticoagulant, antiplatelet, or thrombolytic therapy within 2 weeks prior to treatment that may increase the risk of bleeding, bruising, or other injection-related complications.\n8. Active inflammation, infection, or skin conditions at or near the injection site.\n9. History of keloid or hypertrophic scar formation, or any condition that predisposes the subject to abnormal wound healing, subjects prone to inflammatory skin diseases, or presence of foreign materials at the treatment site.\n10. Pregnant or nursing women, or those planning to become pregnant during the study.\n11. Autoimmune diseases, immunodeficiency disorders, or ongoing immunosuppressive therapy.\n12. Use of immunosuppressive agents or other systemic medications within the past 3 months.\n13. Active infectious disease, including viral hepatitis or syphilis.\n14. Current chronic systemic corticosteroid therapy, defined as continuous systemic corticosteroid use for ≥4 weeks at a dose equivalent to ≥10 mg\u002Fday of prednisone.\n15. Participation in another drug or medical device clinical trial within the past 3 months.\n16. Any other condition that, in the investigator's judgment, makes the subject unsuitable for study participation.\n17. Subjects who are incarcerated or under legal guardianship and are unable to understand the study or provide informed consent.\n18. Subjects with clinically significant severe facial asymmetry, scars, deformities, or other conditions involving the nasolabial fold area that, in the opinion of the investigator, may compromise standardized photographic documentation or reliable assessment of WSRS and GAIS outcomes.",{"count":49,"type":21},100,[24],"This is a multicenter, prospective, non-randomized, uncontrolled post-market clinical follow-up (PMCF) study designed to evaluate the performance and safety of Facetem S dermal filler for the correction of moderate-to-severe nasolabial folds in adult subjects.\n\nSubjects will receive Facetem S treatment at baseline, with an optional touch-up treatment approximately 4 weeks later if clinically necessary. Subjects will be followed for up to 12 months after the final injection to assess wrinkle severity improvement, overall aesthetic improvement, and safety.",[27],[54],"Dermal Filler","2026-09-28",{"date":57,"type":32},"2026-10-02",{"date":59,"type":21},"2027-01",{"date":61,"type":21},"2029-01",{"name":63,"class":39},"CGBio Inc.",5,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100654032","phase-3-study-to-assess-adverse-events-and-how-effective-noa-lift-is-compared-to-juvderm-volift-with-lidocaine-for-the-correction-of-nasolabial-folds-in-adults-100654032","NCT07794878","Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults","A Prospective Multi-Center, Evaluator- and Subject- Blinded, Randomized Study to Evaluate the Safety and Effectiveness of NOA LIFT Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds","Inclusion Criteria:\n\n\\- Moderate (2) or Severe (3) on the 5-point Nasolabial Fold Severity Scale (NLFSS) for each nasolabial fold (NLF) on evaluator live assessment (both sides must qualify and have the same score)\n\nExclusion Criteria:\n\n* Current cutaneous or mucosal inflammatory or infectious processes, abscess, unhealed wound, or cancerous or precancerous lesion in the treatment area(s).\n* Current enrollment in an investigational drug or device study or participation in such a study within 30 days before enrollment.",{"count":73,"type":21},288,[75],"PHASE3","Nasolabial folds (NLFs) are wrinkles that run from the sides of the nose to the corners of the mouth. The goal of this study is to evaluate how safe and effective NOA LIFT is compared to JUVÉDERM VOLIFT with Lidocaine for correcting moderate to severe nasolabial folds in adults.\n\nNOA LIFT and JUVÉDERM VOLIFT with Lidocaine are hyaluronic acid-based dermal fillers being evaluated for the treatment of nasolabial folds. Participants are randomly placed into 1 of 2 treatment groups. There is a 2 in 3 chance that participants will be assigned to the NOA LIFT group and a 1 in 3 chance of being assigned to the VOLIFT group. Around 288 adult participants with moderate to severe nasolabial folds will be enrolled at multiple sites in China.\n\nParticipants will receive deep dermis injections of either NOA LIFT or JUVÉDERM VOLIFT. The study duration is approximately 12 months after the initial treatment.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, vital signs, laboratory tests, vision assessments, checking for side effects, and completing questionnaires.",[27],[27,79,80,81],"NOA LIFT","JUVÉDERM VOLIFT","Lidocaine","RECRUITING","2026-08-27",{"date":85,"type":32},"2026-08-31",{"date":87,"type":32},"2026-08-19",{"date":89,"type":21},"2028-08",{"name":91,"class":39},"AbbVie",6]